JPWO2019145453A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019145453A5 JPWO2019145453A5 JP2020541437A JP2020541437A JPWO2019145453A5 JP WO2019145453 A5 JPWO2019145453 A5 JP WO2019145453A5 JP 2020541437 A JP2020541437 A JP 2020541437A JP 2020541437 A JP2020541437 A JP 2020541437A JP WO2019145453 A5 JPWO2019145453 A5 JP WO2019145453A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune
- arginase
- cell according
- immune cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18153782 | 2018-01-28 | ||
| EP18153782.0 | 2018-01-28 | ||
| PCT/EP2019/051806 WO2019145453A1 (en) | 2018-01-28 | 2019-01-24 | Arginase suppression for cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517454A JP2021517454A (ja) | 2021-07-26 |
| JP2021517454A5 JP2021517454A5 (https=) | 2022-02-24 |
| JPWO2019145453A5 true JPWO2019145453A5 (https=) | 2022-02-24 |
Family
ID=61074351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541437A Pending JP2021517454A (ja) | 2018-01-28 | 2019-01-24 | 癌治療のためのアルギナーゼ抑制 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210177897A1 (https=) |
| EP (1) | EP3743510A1 (https=) |
| JP (1) | JP2021517454A (https=) |
| CN (1) | CN111902532A (https=) |
| AU (1) | AU2019211067A1 (https=) |
| CA (1) | CA3125797A1 (https=) |
| WO (1) | WO2019145453A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3774843B1 (en) | 2018-03-29 | 2022-05-25 | Molecure SA | Dipeptide piperidine derivatives |
| GB201912030D0 (en) * | 2019-08-21 | 2019-10-02 | Cancer Research Tech Ltd | Binding molecules |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431080A1 (en) * | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| EP2010211A4 (en) | 2006-03-23 | 2010-06-09 | Univ Johns Hopkins | ARGINASE II: TARGET FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS |
| EP2083812B1 (en) | 2006-11-21 | 2017-04-05 | Rijksuniversiteit Groningen | Use of arginase inhibitors in the treatment of asthma and allergic rhinitis |
| US9266908B2 (en) | 2011-10-19 | 2016-02-23 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| US20140120136A1 (en) * | 2012-10-12 | 2014-05-01 | The Babraham Institute | Mir-155 enhancement of cd8+ t cell immunity |
| WO2014066137A1 (en) * | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
| ES2897635T3 (es) | 2014-04-29 | 2022-03-02 | Bio Cancer Treat International Ltd | Métodos y composiciones para modular el sistema inmunológico con la arginasa I |
| WO2016187459A1 (en) | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| MX2018005274A (es) | 2015-10-30 | 2019-09-19 | The Regents Of The Universtiy Of California | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. |
| EP3538111B1 (en) * | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
-
2019
- 2019-01-24 AU AU2019211067A patent/AU2019211067A1/en not_active Abandoned
- 2019-01-24 US US16/963,380 patent/US20210177897A1/en not_active Abandoned
- 2019-01-24 CA CA3125797A patent/CA3125797A1/en active Pending
- 2019-01-24 WO PCT/EP2019/051806 patent/WO2019145453A1/en not_active Ceased
- 2019-01-24 CN CN201980021913.2A patent/CN111902532A/zh active Pending
- 2019-01-24 EP EP19705288.9A patent/EP3743510A1/en not_active Withdrawn
- 2019-01-24 JP JP2020541437A patent/JP2021517454A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | From concept to cure: The evolution of CAR-T cell therapy | |
| US20260055157A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| Rui et al. | Cancer immunotherapies: advances and bottlenecks | |
| Khan et al. | Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors | |
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| D’Aloia et al. | CAR-T cells: the long and winding road to solid tumors | |
| US20210338729A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF | |
| KR102186180B1 (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| Escobar et al. | Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens | |
| CN111247168A (zh) | 靶向多种抗原的复合嵌合抗原受体(cCAR)及其组成和使用方法 | |
| US20210130438A1 (en) | Pan-cancer t cell exhaustion genes | |
| Saibil et al. | Targeting T cell activation in immuno-oncology | |
| Tsuchiya et al. | Type I interferon delivery by iPSC-derived myeloid cells elicits antitumor immunity via XCR1+ dendritic cells | |
| JP2020530277A (ja) | 反復投与のための細胞免疫療法 | |
| Testa et al. | CAR-T cell therapy in B-cell acute lymphoblastic leukemia | |
| Hu et al. | Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer | |
| US20250122529A1 (en) | Polycistronic vectors for cell-based therapies | |
| US20220241327A1 (en) | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof | |
| Yu et al. | Revolution of CAR engineering for next-generation immunotherapy in solid tumors | |
| Chen et al. | Natural killer cells: the next wave in cancer immunotherapy | |
| JP2021517454A5 (https=) | ||
| JP2025518033A (ja) | 免疫細胞クリスパースクリーニングのための方法及び組成物 | |
| Cortes-Hernandez et al. | Chimeric antigen receptor (CAR) T cell therapy for cancer. Challenges and opportunities: An overview | |
| Chen et al. | Innovative gene engineering strategies to address tumor antigen escape in cell therapy | |
| Yu et al. | CAR NK cell therapy for solid tumors: Potential and challenges |